BMS - Autoimmune Disease Drugs Business is based in New York City. It has raised $300M in total funding. Latest round: Series A.
BMS - Autoimmune Disease Drugs Business funding overview
BMS - Autoimmune Disease Drugs Business is based in New York City. BMS - Autoimmune Disease Drugs Business has raised $300M in total disclosed funding. That places its disclosed total in the $250M–$1B range. Its most recent disclosed round is a Series A announced in July 2025. The round record for BMS - Autoimmune Disease Drugs Business runs through 2025; nothing later has been disclosed. Investors on record include Bain Capital, Bain Capital Life Sciences. 2 distinct backers are named across the disclosed rounds.
BMS - Autoimmune Disease Drugs Business at a glance
Total raised
$300M
Latest round
Series A
Latest round date
July 2025
Headquarters
New York City
Notable investors
Bain Capital, Bain Capital Life Sciences
Frequently asked about BMS - Autoimmune Disease Drugs Business funding
How much has BMS - Autoimmune Disease Drugs Business raised?
BMS - Autoimmune Disease Drugs Business has raised $300M in total disclosed funding across the rounds on record.
Who has invested in BMS - Autoimmune Disease Drugs Business?
Bain Capital, Bain Capital Life Sciences are named among the investors backing BMS - Autoimmune Disease Drugs Business.
What was the latest BMS - Autoimmune Disease Drugs Business funding round?
The most recent disclosed round is a Series A, announced in July 2025.
Where is BMS - Autoimmune Disease Drugs Business based?
BMS - Autoimmune Disease Drugs Business is based in New York City.
When did BMS - Autoimmune Disease Drugs Business last raise?
The last disclosed BMS - Autoimmune Disease Drugs Business round closed in July 2025 at Series A.
Round data for BMS - Autoimmune Disease Drugs Business is compiled from public filings and announcements; blank fields mean nothing has been disclosed rather than nothing exists. Continue with the companies in New York City and backer lists below.
Companies related to BMS - Autoimmune Disease Drugs Business (36)
